Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine add-on therapy for aggression, agitation, and serum BDNF in Alzheimer's disease dementia
IRCT20170608034390N10Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine in Alzheimer's disease (AD) and Dementia, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Aggression and agitation severity and Serum BDNF levels. Started Jun 2022; status: completed.
02
Drugs
agomelatine
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on IRCT20170608034390N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170608034390N10.